The relative contribution of demographic, lifestyle and medication factors to the association between affective disorders and cardiometabolic diseases is poorly understood.
similar to questions assessing mood disorders within structured diagnostic assessment instruments. To some extent the validity of these questions have been supported internally within this dataset by comparisons of gender distribution, socioeconomic status, self-reported health rating, current depressive symptoms and smoking status (17) . For the purposes of this study, participants were categorised into three groups (Figure 1 ): those with a positive lifetime history of bipolar disorder features, those with features of major depression and a control group (17, 19) . 'Any cardiovascular disease' was defined as the self-report of a previous physician diagnosis of hypertension, MI, angina and/or stroke. Diabetes was also defined by self-report. BMI was determined though anthropometric measurements carried out at the assessment centre and categorised into underweight (<18.5 kg/m 2 ), normal weight (18.5-24.9 kg/m 2 ), overweight (25.0-29.9 kg/m 2 ), class I obese (30.0-34.9 kg/m 2 ), class II obese (35.0-39.9 kg/m 2 ) and class III obese (≥40 kg/m 2 ) (20) .Smoking status, frequency of alcohol consumption and ethnic group were self-reported on the touchscreen questionnaire. Smoking status was classified as 'current smoker', 'previous smoker' or 'never smoked' and alcohol use was classified as 'daily/almost daily', '3-4 times per week', '1-2 times per week', '1-3 times/month', 'special occasions only' or 'never'. Ethnicity was categorised as: 'white', 'mixed', 'Asian/Asian British', 'black/black British', 'Chinese', and 'other'. The Townsend deprivation index -an area-based measure of socioeconomic status derived from information collected in the census on car ownership, overcrowding, owneroccupation and unemployment -includes both positive and negative values, with positive values indicating higher levels of deprivation (20) . Townsend scores were divided into quintiles (within the study population) to facilitate comparisons. The use of current medication (including psychotropics) was self-reported by participants and a comprehensive list of commonly used psychotropics was identified (Appendix 3). Participants were classified as using psychotropic medication if they reported currently taking any of these medications.
Statistical analyses
Differences in baseline characteristics between the three groups (control, depressive features and bipolar features) were analysed using the chi-squared test for categorical data, and the chi-squared test for trend for ordinal data.We used separate logistic regression models to examine the associations between mood group (independent variable) and cardiometabolic disease categories ('any cardiovascular disease' (not including diabetes), diabetes, hypertension, myocardial infarction, angina or stroke) (dependent variable),with controls as the referent group. Models were initially adjusted for age, sex, socioeconomic deprivation and ethnicity (the partially adjusted model) and then repeated including additional covariates: smoking status, frequency of alcohol use, BMI and the use of psychotropic medication (fully adjusted model). Interaction tests for sex were undertaken and subgroup analyses carried out as appropriate.
In order to explore the relative contribution of psychotropic medication to cardiometabolic risk across the mood spectrum, we carried out a sub analysis to assess the effect of current psychotropic medication and mood group status on cardiometabolic disease across the mood spectrum. Six groups were created: individuals with no mood disorder features and not currently taking psychotropic medication (our referent group); individuals with no mood disorder features but currently taking one or more psychotropic medications; individuals with depressive features not currently taking psychotropic medication; individuals with depressive features currently taking one or more psychotropic medications; individuals with features of bipolar disorder not currently taking any psychotropic medication; and individuals with features of bipolar disorder currently taking psychotropic medication.
Differences in cardiometabolic outcomes between different mood and medication status groups were
reported as prevalences and then analysed using the chi-squared test for categorical data. We again used separate logistic regression models to examine associations between medication and mood disorder group with cardiometabolic disease (diabetes, myocardial infarction, angina, hypertension or stroke). As noted above, controls who were not currently taking psychotropic medication were chosen as the most appropriate referent group. These models were adjusted for age, sex, socio-economic deprivation and ethnicity, smoking, alcohol and BMI.
All statistical analyses were performed using Stata version 12.1 (StataCorp, College Station, Texas).
Statistical significance was defined conservatively as p<0.001.
Results

Group characteristics: bipolar features, depression features and controls
A total of 172,751 UK Biobank participants were assessed at baseline with respect to lifetime history of depressive and bipolar features. Of these, complete data on mood disorder features and cardiometabolic disease status were available for 145,991 (84.5%). From this sample, according to our criteria within Figure 1 , 1,557 (1.06%) had features of bipolar disorder, 30,991 (21.23%) had features of major depression and 113,447 (77.71%) had no significant features of mood disorder (controls) ( Table   1) .
Participants with features of bipolar disorder were younger and more likely to be female (Table 1) .
Current smoking was most common in the bipolar features group (21.3%), followed by the depressive features group (12.7%) and then the non-mood-disordered control group (8.8%) ( Table 1) . The proportions of different levels of socioeconomic deprivation were mixed between the groups, but of note was that 34.6% of the bipolar features group were in the most deprived quintile, compared to 22.4% for the depressive features group, and 19.2% for the control group. White ethnicity was most common in the depressive features group and least common in the bipolar features group (Table 1) .
Patterns of alcohol use were similar between groups and obesity was more common in both the depressive features and bipolar features groups compared to controls. Rates of current psychotropic medication use were highest in the groups with bipolar (32.1%) and depressive (20.6%) features and lowest within the control group (3.4%).
Prevalence of Cardiometabolic Disease
The prevalence of 'any cardiovascular disease' was highest in the bipolar features group (34.5%), followed by the depressive features group (30.6%) and lowest in the control group (28.7%) ( Table 1) .
Similar patterns were observed for hypertension, myocardial infarction, angina and stroke.
Cardiometabolic disease frequencies were also calculated for men and women. Men had consistently higher rates of all cardiometabolic diseases and, in general, rates of cardiometabolic disease were highest in the bipolar features group, followed by the depressive features group and the control group (Table 1 ).
Partially adjusted model
On multivariate logistic regression (adjusting for age, sex, socio-economic deprivation and ethnicity) odds ratios (OR) for all cardiometabolic outcomes were significantly increased in the depressive features and the bipolar features group relative to controls (all p<0.001, Table 2 ). In general, the odds of each cardiometabolic outcome, as well as the odds of having 'any cardiovascular illness', increased across the two mood groups, in the depressive features group and the bipolar features group ( Table 2 ).
It should be noted, however, that findings for the bipolar features group with respect to diabetes and stroke were not statistically significant. There was a significant interaction between mood disorder and sex in predicting risk of having 'any cardiovascular illness' (p<0.001) and sub-group analyses by sex were subsequently carried out. Men with bipolar features had elevated odds ratios for myocardial infarction ( 
Fully adjusted model
On additional adjustment for smoking status, frequency of alcohol consumption, BMI and the use of psychotropic medication, the risk of having 'any cardiovascular illness' remained significantly elevated in both the depressive (OR=1.15 p<0.001, 95%CI 1.12-1.19) and the bipolar features groups (OR=1.28 p<0.001, 95%CI 1.14-1.43) ( Table 2 ). This pattern was also largely present in a subgroup analysis by sex ( Table 2 ). In the fully adjusted model, odds ratios for hypertension and myocardial infarction were also significantly elevated in the combined male and female groups (hypertension: depression: OR=1.15 p<0.001, 95%CI 1.12-1.13, bipolar: OR=1.26, p<0.001, 95%CI 1.12-1.42) (myocardial infarction: depression: OR=1.18, p<0.001, 95%CI 1.08-1.30) ( Table 2) .
Differences in odds ratios for angina and stroke within the fully adjusted, combined group analyses were not statistically significant. There were, however, significant elevations in odds of cardiovascular conditions within the depressive features group, most notably for stroke (OR=1.26, p<0.01, 95%CI 1.13-1.40) ( Table 2 ). Associations with diabetes were not significant in the fully adjusted model in either the depressive features or bipolar features groups. Odds ratios were reduced by approximately a quarter for many of the outcome measures upon the additional adjustment for BMI, smoking, alcohol consumption and psychotropic medication.
Current use of any psychotropic medication
We carried out a sub-analysis to assess the contribution of current psychotropic medication use to cardiometabolic risk across the mood spectrum (from controls through depression and bipolar). 109,577 individuals without features of mood disorder who were not taking psychotropic medication were identified as a control group (Table 3 ). There were 3,867 individuals who did not meet the criteria for depressive or bipolar features but who reported taking one or more psychotropic medications (Table 3) . Although the indication for these medications was not known, this group displayed higher prevalences of all cardiometabolic diseases compared to controls. Of particular note were elevated rates of diabetes (8.97%), angina (5.87%), hypertension (36.07%) and stroke (3.98%) ( Table 3 ).
Compared to the control group, individuals with depressive features who reported no current psychotropic use showed similar rates of diabetes, myocardial infarction, angina, hypertension and stroke and those with depressive features taking psychotropic medication had higher rates of all cardiometabolic diseases, with rates of diabetes (8.31%) and MI (3.52%) notably higher than controls (Table 3 ). It should be noted however that, with the exception of MI, rates of cardiometabolic disease in this group were not significantly elevated relative to controls currently on psychotropic medication.
Rates of cardiometabolic disease in individuals with bipolar features but who were not taking psychotropic medication (n=1057) were elevated compared to controls. Rates of diabetes (5.68%), MI (2.84%), angina (3.69%), hypertension (30.18%) and stroke (1.70%) in this group were all higher than controls ( Table 3 ).Cardiometabolic diseases were most common for individuals with bipolar features who were also taking psychotropic medication (diabetes (9.60%), MI (5.00%) and stroke (3.20%)) ( Table   3 ).
Fully adjusted medication analyses
To assess the relative contribution of current psychotropic medication use in cardiometabolic disease across the mood spectrum we carried out a multivariate logistic regression adjusting for age, sex, socioeconomic deprivation, ethnicity, smoking status, frequency of alcohol consumption and BMI (Table   4 , Figures 2a-2e ). In general, odds ratios for most cardiometabolic diseases remained significantly elevated in each of the mood and medication groups relative to controls ( Table 4 and figures 2a-2e).
Exceptions were for diabetes in the depressive features group not taking psychotropic medication, the bipolar features group not taking psychotropic medication, and the bipolar group currently taking psychotropic medication. Increases in odds ratios in the bipolar features not on psychotropic medication group were also not significantly elevated for angina (OR, 1.58 95%CI 1.22, 2.06, p < 0.001) and stroke (OR 1.70, 95%CI 1.20, 2.41, p = 0.003).
Furthermore, odds ratios for angina and stroke were not significantly elevated for both the bipolar features groups (those currently not taking psychotropic medication, as well as those taking psychotropic medication) ( In general, however, the odds of reporting a history of an adverse cardiometabolic outcome were associated with both psychotropic medication use and with mood disorder ( Table 4 , figures 2a-2e) and the size of these associations increased with mood disorder severity (from depression to bipolar).
Discussion
We found that in a very large population sample of adults with lifetime features of depression and bipolar disorder, there was an increased risk of comorbid cardiovascular disorders, even after adjusting for a wide range of confounding factors. In general, these associations were more pronounced for individuals withfeatures of bipolar disorder than for features of depression. Perhaps unsurprisingly, we also identified an association between current use of psychotropic medication and risk of cardiometabolic disease in individuals with a history of depressive and bipolar features. It is, however notable that this association also occurred in individuals with no definite history of mood disorder who were currently taking psychotropic medication.
Both the bipolar features and depressive features groups had significantly higher odds ratios for 'any cardiovascular disease' relative to controls, within partially and fully adjusted models. Given the broad range of common confounding variables that were adjusted for, this suggests an independent association between mood disorder and cardiometabolic diseases.
Within the partially adjusted (for age, sex, deprivation, ethnicity) versus fully adjusted models (additionally adjusted for BMI, smoking status, alcohol consumption and psychotropic medication), odds ratios for 'any cardiovascular disease' fell from 1.29 (partial) to 1.15 (full) within the depressive features group and from 1.50 (partial) to 1.28 (full) in the bipolar features group. Although depression has been considered a risk factor for cardiovascular disease for some time (21) , there has been debate about the relative contribution of lifestyle factors for this group of patients. We have been able to control for some of these lifestyle factors.
Limitations
The strengths of this study include the general population design, breadth of coverage of confounding factors and the very large sample size.However, several limitations are acknowledged. Cardiometabolic disorders previously diagnosed by a physician were self-reported by the participants. Similarly, mood disorder features were self-reported, rather than assessed using a formal diagnostic interview, although a structured approach was used ( Figure 1 ). Psychiatric diagnoses based on formal interviews were notpracticalwithin UK Biobank, so we tooka pragmatic approach to mood disorder groupings. It is possible that our criteria for mood disorder are less stringent than formal diagnostic criteria.
It should be noted, however, that we are reporting features of mood disorders at a population level, rather than formal clinical diagnoses and we were unable to validate diagnoses due to lack of availability of definitive diagnostic information. This has implications in terms of the likely sensitivity and specificity of our groupings, which are based on self-report.Linkage to routine hospital and general practice health records will be available in the future and will allow validation of our groupings.
There is however some evidence for the validity of these groupings using internal variables (21) , for example, the sex distributions of approximately 1:1 for bipolar disorder and approximately 2:1 (women: men) for depression are consistent with a large body of epidemiological research on lifetime rates of mood disorder in men and women (22, 23) . Furthermore, the lifetime prevalence rates for bipolar disorder (1.1%) and recurrent major depressive disorder (21.2%) are consistent with other populationbased lifetime estimates (17) . In the future, linkage of UK Biobank participants to routine health records will be possible and will help to address some of these limitations.
Although we are reasonably confident that members of the control group did not have significant features of depression or bipolar disorder, it should be noted that a proportion may have fulfilled criteria for other mental illnesses, such as anxiety disorder or, less likely, schizophrenia, both of which have been associated with poor cardiometabolic health (24)(25) (26) .
There are also limitations with our broad definition of "current psychotropic medication use", which groups together different classes of medication. In a sub-analysis of individuals on psychotropic monotherapy, we found that SSRIs, other antidepressants and sedatives/hypnotics were all associated with greater risk of MI relative to psychotropic-free controls (SSRIs OR 1.82, 95%CI 1.51-2.21; other antidepressants OR 1.50, 95%CI 1.20-1.87; and sedatives/hypnotics OR 2.53, 95%CI 1.76-3.66). It is therefore possible that adverse cardiovascular outcomes in depressive disorders are not limited to the use of antipsychotics but may also be a consequence of other classes of psychotropic medications.
It is also the case that a relatively low proportion of the mood disorders features groups reported taking psychotropic medication (bipolar features 32.1%, depressive features 20.6% and controls 3.4%) but, as noted above, the focus in this study was not clinically-diagnosed mood disordered groups but rather lifetime features of mood disorder at a population level. Compliance with medication is a major issue in the management of mental illness.
According to some estimates up to 50% of patients prescribed psychotropic medication do not comply with their proposed medication (27) (28) (29) . Although compliance with physical medication may be slightly better than this (30) , it is likely that the factors which cause poor compliance with psychotropic medication may also lead to poor compliance with cardiovascular medications in this group. This might explain the proportionately worse cardiovascular outcomes in a less compliant mood disordered group compared to a more compliant non-mood disordered group. Due to the level of information on medication status which was collected at baseline, we were unable to assess the impact of duration of exposure to psychotropic medication on adverse cardiometabolic outcomes.
We included a range of possible confounding variables in the regression models but were unable to control for physical activity. The available data on physical activity was not collected in terms of standardised measures. Unfortunately, it was not possible to create a standardised measure, such as the Metabolic Equivalent of Task (MET).Similarly, we were unable to adjust for the potential confounding effects of diet. When considering appropriate variables to include as confounding variables, it is important to note that there is uncertainty as to the extent that these variables might represent confounders or mediators. For example, obesity may represent an important component of the pathophysiology for depression, bipolar disorder and coronary heart disease. A prospective cohort study is required to address these concerns and is planned as part of future work in this cohort.
Our analyses did not assess the additive effects of sociodemographic and lifestyle factors. Rather, given the large number of confounding factors involved, we took a broad approach, focussing on cardiovascular outcomes after partial and full adjustment for confounders.
Severity of mood disorder may have contributed to the associations we observed. We therefore conducted an additional analysis of the impact of illness severity on the cardiovascular disease outcomes. The depressive features group were divided into those who had a history of a probable single episode of major depression, versus those with a history of probable moderate recurrent depression and those with probable severe recurrent depression (figure 1). The bipolar group was also split into those with features of probable bipolar type one illness and those with features of probable bipolar type two illness (figure 1). In general, individuals in the more severe mood disorder groups had higher risk of adverse cardiovascular outcomes. For the bipolar type one group the OR of 'any cardiovascular illness' was 1.39 (95%CI 1.23-1.58), for the recurrent severe depression group the OR was 1.33 (95%CI 1.18-1.50) and for the bipolar type two group the OR was 1.21 (95%CI 1.09-1.32).
Findings in the context of previous work
Many studies have investigated the association between depressive illness and cardiovascular disease and the association is well established (31) . Relatively fewer studies have examined the association between bipolar disorder and cardiovascular disease. Although reports in the literature support the association between bipolar disorder and cardiovascular disease(4)(32)(33)(34), these studies have not been able to adjust for the same variety of potential confounding factors as in our study.Relative to controls, women with features of bipolar disorder had a greater risk of 'any cardiovascular disease' than men with bipolar features (OR 1.36 versus 1.19). This finding may be particularly noteworthy given that men are known to have increased rates of cardiovascular disease within the general population. In their 2013 population study, Crump and colleagues (33) reported increased all-cause mortality for women with bipolar disorder compared to men with bipolar disorder (adjusted hazard ratio of 2.13 compared to 1.74). Furthermore, the same study reported higher hazard ratios of death from ischaemic heart disease for women with bipolar disorder compared to men with bipolar disorder (2.14 compared to 1.73). Our findings add to the evidence that women with bipolar disorder may be disproportionately affected by cardiovascular disease.Our findings also highlight other, more specific interactions between mood disorder and gender with respect to the association with cardiometabolic disease. In our fully adjusted model for individuals with depressive or bipolar features, men (but not women) had an increased risk of MI, and women (but not men) were at higher risk of stroke (Table 2) . There are several possible explanations for this, including studies which have found that men are more likely to receive a diagnosis of MI than women (35) and that stroke is more commonly diagnosed in middle-aged women than in men (36) . Differential rates of diagnosis of MI may in part be due to the use of troponin levels for diagnosis (troponin concentrations correlate with left ventricular mass (37, 38) which is greater in men (39) . The increased risk of stroke in middle-aged women compared to men could be explained by several factors, including increased systolic blood pressure, increased total cholesterol and inadequate risk factor modification in women (36) .
Possible mechanisms
Our study adds to the literature on the associations and covariates of increased cardiometabolic morbidity and mortality in mood disorder. There are numerous possible underlying mechanisms for these associations, for example, shared behavioural factors, inequalities in treatment, shared genetic vulnerabilities and shared underlying pathophysiology.
Individuals with mood disorder may have difficulties in accessing preventative medical interventions as
well as having higher rates of risky lifestyle factors (40) . Such factors include including smoking, physical inactivity and reduced compliance with cardiovascular medications (41, 42) . Individuals with depression tend to exercise less and have lower exercise capacity (52, 53, 54) . Furthermore, rates of current smoking have also been found to be approximately double in those experiencing depressive symptoms compared to non-mood-disordered controls (50) (43) . Individuals with depression and bipolar disorder are also at increased risk of obesity and the combination of sedentary lifestyle, smoking and obesity confers a significant additive risk for cardiovascular disease (50) . Other relevant lifestyle factors include increased rates of drug and alcohol use in individuals with mood disorder (44, 45) .
Inflammatory pathways are also likely to be relevant to the overlap between mood disorders and cardiometabolic disease. Proinflammatory cytokines are implicated in atherosclerosis (46, 47) and individuals with depression are known to have elevated serum levels of inflammatory markers (47) .
Additionally, a depressed mental state in patients receiving angioplasty has been shown to be positively correlated with serological markers of inflammation, furthering the case for a role of inflammation in the association between mood disorder and cardiovascular disease (48) .
Oxidative stress is also thought to be relevant when considering potential mechanisms for the association. Markers of oxidative stress including superoxide dismutase and malondialdehyde have been reported as higher in depressed subjects and have also been shown to reduce upon pharmacological treatment of depression (49) .
The role of the hypothalamic pituitary axis (HPA) is also relevant. HPA axis abnormalities are associated with a variety of cardiometabolic diseases including ischaemic heart disease, stroke and type 2 diabetes(50). Moreover, there is some evidence that individuals with severe depression or bipolar disorder may have significantly elevated rates of HPA axis dysfunction(51, 52) (53) .
Endothelial dysfunction should also be considered as a potential underlying mechanism for the association between mood disorder and cardiometabolic disease. There are reports in the literature that both depression and bipolar disorder (54) are linked to endothelial dysfunction. Endothelial dysfunction has been proposed as a potential cause for a variety of cardiometabolic diseases including hypertension, hypercholesterolemia, obesity and type 2 diabetes (54)(55).
Although both depression and coronary heart disease are known to be influenced by genetic factors (56) (57) (58) , there has been relatively little work investigating shared genetic risk factors between the two disorders (57). Scherrer and colleagues reported on the associations between hypertension and coronary heart disease in 6,903 male-male twins from the Vietnam Era Twin Registry (57) and found significant genetic correlations between depressive symptoms and both hypertension and coronary heart disease (57) . In addition, there has been work on a possible genetic link between bipolar disorder and type 2 diabetes-one genome wide association study found that bipolar disorder and type 2 diabetes shared 68 single nucleotide polymorphisms (SNPs) (59) . In our study with respect to diabetes, odds ratios for individuals with depression were significantly higher in the partially adjusted model but not in the fully adjusted model, perhaps because of the association between diabetes and both obesity (60) and psychotropic medications (61, 62).
It is also appropriate to consider the effect of psychological stress on haemodynamic reactivity and systolic blood pressure (63) . Our findings that the odds ratios for hypertension were increased in both depressive features and bipolar features relative to controls could possibly be related to differences in haemodynamic reactivity. Heightened cardiovascular reactivity seen in chronic stress may also be associated with the triggering of acute coronary events and the development of atherosclerosis (63) .
The effects of psychotropic medication should also be considered. The metabolic effects of psychotropic medications are known to increase cardiometabolic risk by various mechanisms including weight gain (64) , and impaired glucose tolerance (65) .Psychotropic medication (appendix 3) was associated with cardiometabolic disease (even in the absence of mood disorder features) and that this effect increased across the mood disorder spectrum, from depressive features to features of bipolar disorder.
Given that our analyses were conducted on the basis of current use of any psychotropic medication, it is perhaps noteworthy that adverse cardiometbolic effects may not be limited to antipsychotics. There are reports in the literature of other psychotropic medications used in the treatment of mood disorder, such as antidepressants, lithium and valproic acid, having adverse metabolic effects (66) (67) (68) . Our finding that psychotropic medication is an important factor in the development of cardiometabolic disease in the depressive features and the control group adds weight to this.
Future work
There remain several unanswered questions and opportunities for further research. To date, very few studies have tested specific genetic associations between lifestyle-related risk factors for cardiometabolic disease and the broad spectrum of mood disorders. There is a need for longitudinal and mechanistic studies in this area to better understand causal pathways (69). In addition, further mechanistic studies examining genetic and epigenetic factors as well as oxidative stress, endothelial dysfunction and HPA axis abnormalities, are essential to better understand the associations between mood disorder and cardiometabolic disease.
Conclusions
Overall, within a large, representative population cohort of UK adults in middle age, we identified associations between lifetime features of mood disorders and cardiovascular diseases which in general were more pronounced for features of bipolar disorder than for features of major depression. These findings persisted even after adjusting for several confounding factors, including current psychotropic medication use, which also increased risk for cardiometabolic disease in individuals without a clear history of mood disorder.
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Bipolar disorder features:
1. Features of bipolar disorder, type I: Ever 'manic or hyper' for at least 2 days OR ever 'irritable/argumentative' for 2 days; plus at least 3 features from 'more active', 'more talkative', 'needed less sleep' and 'more creative/more ideas'; plus duration of a week or more; plus 'needed treatment or caused problems at work'.
Features of bipolar disorder, type II:
Ever 'manic or hyper' for at least 2 days OR ever 'irritable/argumentative' for 2 days; plus at least 3 features from 'more active', 'more talkative', 'needed less sleep' and 'more creative/more ideas'; plus duration of a week or more.
Major depression features:
1. Features of single episode major depression: Ever depressed/down for a whole week; plus at least two weeks duration; plus only one episode; plus ever seen a GP or a psychiatrist for 'nerves, anxiety, depression' OR ever anhedonic (unenthusiasm/uninterest) for a whole week; plus at least two weeks duration; plus only one episode; plus ever seen a GP or a psychiatrist for 'nerves, anxiety, depression'.
Features of recurrent major depression (moderate):
Ever depressed/down for a whole week; plus at least two weeks duration; plus at least two episodes; plus ever seen a GP (but not a psychiatrist) for 'nerves, anxiety, depression' OR ever anhedonic (unenthusiasm/uninterest) for a whole week; plus at least two weeks duration; plus at least two episodes; plus ever seen a GP (but not a psychiatrist) for 'nerves, anxiety, depression'.
Features of recurrent major depression (severe):
Ever depressed/down for a whole week; plus at least two weeks duration; plus at least two episodes; plus ever seen a psychiatrist for 'nerves, anxiety, depression' OR ever anhedonic (unenthusiasm/uninterest) for a whole week; plus at least two weeks duration; plus at least two episodes; plus ever seen a psychiatrist for 'nerves, anxiety, depression'. Figure 2d ) Logistic regression analysis of stroke associated with mood disorder and medication status. Controls not on psychotropic medication
